James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

5 Biotech Stocks That Are Buyout Candidates

These biotech stocks are this year's top M&A candidates. But even if they're not acquired, they're solid biopharma investments.

For-Profit Schools Can’t Dodge This Bullet Any Longer

For-profit schools like Corinthian College, Apollo Education and Strayer are forced to defend themselves, and as it turns out, they’re not well-armed.

This Biotech Bubble Is Bound to Burst

Biotech stocks have been hot thanks to a wave of M&A speculation. That wave, however, has run its course, putting these stocks and biotech ETFs at risk.

YNDX, BIDU or GOOG: Which Is the Best Search Stock?

GOOG may have set the bar, but YNDX stock and BIDU stock have managed to replicate the search giant's success in their respective markets. Which is best?

SCTY Stock Continues Crushing Other Solar Stocks

SCTY stock is blowing other solar stocks out of the water. Here's why First Solar and others can't keep up with SolarCity.